I’m a huge fan of early stage deals with lots of upside and a cost under $75M.
GlaxoSmithKline, looking to shore up their hepatitis C pipeline, announced that they have entered into an agreement with Genelabs Technologies for approximately $57 million (£35 million) through a tender offer of $1.30 per share in cash.
GlaxoSmithKline to acquire Genelabs Technologies to increase focus on novel small molecule therapies for Hepatitis C
-(Via GSK news.)
![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_e.png?x-id=f43e5b74-b898-42ca-bc29-9adb2bf92767)
Theoretically Related Posts
This post was constructed by .
Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.
If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.
Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.
If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.
Add New Comment
Thanks. Your comment is awaiting approval by a moderator.
Do you already have an account? Log in and claim this comment.
Add New Comment
Trackbacks
(Trackback URL)